Compare ConocoPhillips (COP) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Eli Lilly And Co — how do they compare? ConocoPhillips trades at $111.54 (market cap $136.29B), while Eli Lilly And Co trades at $1,153.92 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 7.6× ConocoPhillips's market cap, and ConocoPhillips pays the higher dividend (3%). Which is the better fit depends on your goals.
| COP | LLY | |
|---|---|---|
Market Cap | $136.29B | $1.03T |
Sector | Energy | Health |
52-Week High | $133.80 | $1.24K |
52-Week Low | $85.66 | $625.65 |
Enterprise Value | $153.25B | $1.07T |
Dividend Yield | 3% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
